Pharming appoints new CMO and CSO
Dutch specialty pharma company Pharming Group (Euronext: PHARM) said today it has appointed Anurag Relan as chief medical officer (CMO), effective immediately, and Robert Friesen as chief scientific officer, effective from August 1, 2021.
They will be the successors of Bruno Giannetti, who was chief operating officer (2006 - 2019) and CMO from 2019. Mr Giannetti announced his retirement from the executive committee at Pharming’s recent Annual General Meeting of Shareholders; he will stay with the company on a consultancy basis.
Mr Relan is currently vice president, clinical research and medical affairs at Pharming, having held a number of roles within the company during the past 15 years. During his tenure, he led the clinical development and subsequent US and European approval of Ruconest (conestat alfa) for the treatment of acute attacks of hereditary angioedema. More recently, he was instrumental in establishing Pharming’s US medical affairs organization and plays an important role in the evaluation of in-licensing and acquisition projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze